Belén P Solans1,2, Robert Chiesa3, Bilyana Doncheva4, Helen Prunty5, Paul Veys3, Iñaki F Trocóniz1,2, Joseph F Standing4,6,7. 1. Pharmacometrics and Systems Pharmacology, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain. 2. IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. 3. Bone Marrow Transplantation Department, Great Ormond Street Hospital for Children, London, UK. 4. Department of Pharmacy, Great Ormond Street Hospital for Children, London, UK. 5. Department of Chemical Pathology, Great Ormond Street Hospital for Children, London, UK. 6. Infection, Immunity, Inflammation Programme, UCL Great Ormond Street Institute of Child Health, London, UK. 7. Paediatric Infectious Diseases Group, St George's, University of London, UK.
Abstract
AIMS: Busulfan and treosulfan are cytotoxic agents used in the conditioning regime prior to paediatric haematopoietic stem cell transplantation (HSCT). These agents cause suppression of myeloid cells leaving patients severely immunocompromised in the early post-HSCT period. The main objectives were: (i) to establish a mechanistic pharmacokinetic-pharmacodynamic (PKPD) model for the treatment and engraftment effects on neutrophil counts comparing busulfan and treosulfan-based conditioning, and (ii) to explore current dosing schedules with respect to time to HSCT. METHODS: Data on 126 patients, 72 receiving busulfan (7 months-18 years, 5.1-47.0 kg) and 54 treosulfan (4 months-17 years, 3.8-35.8 kg), were collected. In total, 8935 neutrophil count observations were recorded during the study period in addition to drug concentrations to develop a mechanistic PKPD model. Absolute neutrophil count profiles were modelled semimechanistically, accounting for transplant effects and differing set points pre- and post-transplant. RESULTS: PK were best described by 2-compartment models for both drugs. The Friberg semimechanistic neutropenia model was applied with a linear model for busulfan and a maximum efficacy model for treosulfan describing drug effects at various stages of neutrophil maturation. System parameters were consistent across both drugs. The HSCT was represented by an amount of progenitor cells enhancing the neutrophils' proliferation and maturation compartments. Alemtuzumab was found to enhance the proliferative rate under which the absolute neutrophil count begin to grow after HSCT. CONCLUSION: A semimechanistic PKPD model linking exposure to either busulfan or treosulfan to the neutrophil reconstitution dynamics was successfully built. Alemtuzumab coadministration enhanced the neutrophil proliferative rate after HSCT. Treosulfan administration was suggested to be delayed with respect to time to HSCT, leaving less time between the end of the administration and stem cell infusion.
AIMS: Busulfan and treosulfan are cytotoxic agents used in the conditioning regime prior to paediatric haematopoietic stem cell transplantation (HSCT). These agents cause suppression of myeloid cells leaving patients severely immunocompromised in the early post-HSCT period. The main objectives were: (i) to establish a mechanistic pharmacokinetic-pharmacodynamic (PKPD) model for the treatment and engraftment effects on neutrophil counts comparing busulfan and treosulfan-based conditioning, and (ii) to explore current dosing schedules with respect to time to HSCT. METHODS: Data on 126 patients, 72 receiving busulfan (7 months-18 years, 5.1-47.0 kg) and 54 treosulfan (4 months-17 years, 3.8-35.8 kg), were collected. In total, 8935 neutrophil count observations were recorded during the study period in addition to drug concentrations to develop a mechanistic PKPD model. Absolute neutrophil count profiles were modelled semimechanistically, accounting for transplant effects and differing set points pre- and post-transplant. RESULTS: PK were best described by 2-compartment models for both drugs. The Friberg semimechanistic neutropenia model was applied with a linear model for busulfan and a maximum efficacy model for treosulfan describing drug effects at various stages of neutrophil maturation. System parameters were consistent across both drugs. The HSCT was represented by an amount of progenitor cells enhancing the neutrophils' proliferation and maturation compartments. Alemtuzumab was found to enhance the proliferative rate under which the absolute neutrophil count begin to grow after HSCT. CONCLUSION: A semimechanistic PKPD model linking exposure to either busulfan or treosulfan to the neutrophil reconstitution dynamics was successfully built. Alemtuzumab coadministration enhanced the neutrophil proliferative rate after HSCT. Treosulfan administration was suggested to be delayed with respect to time to HSCT, leaving less time between the end of the administration and stem cell infusion.
Authors: Belén P Solans; Robert Chiesa; Bilyana Doncheva; Helen Prunty; Paul Veys; Iñaki F Trocóniz; Joseph F Standing Journal: Br J Clin Pharmacol Date: 2020-03-03 Impact factor: 4.335
Authors: Coco de Koning; Jurgen Langenhorst; Charlotte van Kesteren; Caroline A Lindemans; Alwin D R Huitema; Stefan Nierkens; Jaap Jan Boelens Journal: Biol Blood Marrow Transplant Date: 2018-10-23 Impact factor: 5.742
Authors: M Sandström; M O Karlsson; P Ljungman; Z Hassan; E N Jonsson; C Nilsson; O Ringden; G Oberg; A Bekassy; M Hassan Journal: Bone Marrow Transplant Date: 2001-10 Impact factor: 5.483
Authors: Yanping Hu; Michael J Turner; Jacqueline Shields; Matthew S Gale; Elizabeth Hutto; Bruce L Roberts; William M Siders; Johanne M Kaplan Journal: Immunology Date: 2009-10 Impact factor: 7.397
Authors: Mary A Slatter; Kanchan Rao; Intan Juliana Abd Hamid; Zohreh Nademi; Robert Chiesa; Reem Elfeky; Mark S Pearce; Persis Amrolia; Austen Worth; Terence Flood; Mario Abinun; Sophie Hambleton; Waseem Qasim; Hubert B Gaspar; Andrew J Cant; Andrew R Gennery; Paul Veys Journal: Biol Blood Marrow Transplant Date: 2017-11-16 Impact factor: 5.742
Authors: Belén P Solans; Robert Chiesa; Bilyana Doncheva; Helen Prunty; Paul Veys; Iñaki F Trocóniz; Joseph F Standing Journal: Br J Clin Pharmacol Date: 2020-03-03 Impact factor: 4.335